2X Blend: Tesamorelin (10mg) / Ipamorelin (5mg) FAT LOSS / LEAN MUSCLE 1.5mg to 4.5mg (10 to 30 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted — 45 minutes before and after injection. Best overall blend for body composition, anti-aging, and heavy fat loss. Tesamorelin drives endogenous GH release and reduces visceral fat; Ipamorelin amplifies GH pulse without increasing cortisol or appetite. Combine in the same syringe.
Dosing Calculator
Recommended: 1.0ml BAC water → 15.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: June 2026 2X Blend: CJC No DAC (5mg) / Ipamorelin (5mg) FAT LOSS / LEAN MUSCLE 2mg to 4mg (20 to 40 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted — 45 minutes before and after injection. Excellent blend for athletes seeking lean muscle tissue development and fat-to-muscle conversion. CJC-1295 No DAC provides a short-acting GHRH pulse; Ipamorelin amplifies the GH signal cleanly.
Dosing Calculator
Recommended: 2.0ml BAC water → 2.5 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 2X Blend: Tesamorelin (5mg) / Ipamorelin (5mg) FAT LOSS / LEAN MUSCLE 2mg to 4mg (20 to 40 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted — 45 minutes before and after injection. Great blend for muscle retention, anti-aging, and reducing fat in stubborn areas. Tesamorelin is FDA-approved for visceral fat reduction; Ipamorelin keeps cortisol and prolactin unaffected.
Dosing Calculator
Recommended: 2.0ml BAC water → 2.5 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 3X Blend: Tesamorelin (5mg) / Ipamorelin (2.5mg) / MGF (500mcg) FAT LOSS / LEAN MUSCLE 1.6mg to 3.2mg (20 to 40 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted — 45 minutes before and after injection. Best blend for the competitive athlete focused on recovery, anti-aging, and adding lean muscle mass. MGF activates satellite cells for muscle repair; Tesamorelin and Ipamorelin amplify the GH axis.
Dosing Calculator
Recommended: 2.0ml BAC water → 2.5 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 4X Blend: Tesamorelin (5mg) / Ipamorelin (2.5mg) / GHRP-2 (5mg) / MGF (500mcg) FAT LOSS / LEAN MUSCLE 2.6mg to 5.2mg (20 to 40 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted — 45 minutes before and after injection. Advanced bulking blend designed to increase muscle mass and drive appetite. GHRP-2 stimulates ghrelin for increased caloric drive alongside the GH-amplifying trio. Best suited for lean bulk phases.
Dosing Calculator
Recommended: 2.0ml BAC water → 2.5 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Semaglutide (GLP-1): 2mg WEIGHT MANAGEMENT Titrate up from 250mcg to 2.5mg (12 to 125 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Starting dose is 250mcg. GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals the hypothalamus to reduce appetite. Approximately 15% mean body weight reduction in clinical trials. Common side effects include nausea, especially during dose escalation. Regulatory notice (May 2026): FDA proposed removing Semaglutide from the 503B compounding bulks list — verify current legal status before sourcing compounded versions. Regulatory note (June 2026): The FDA has proposed formally excluding semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list. The public comment period closes June 29, 2026. Compounding availability may change — consult a licensed compounding pharmacy for current status.
Dosing Calculator
Recommended: 1.0ml BAC water → 2.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Semaglutide (GLP-1): 5mg WEIGHT MANAGEMENT Titrate up from 250mcg to 2.5mg (5 to 50 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Starting dose is 250mcg. GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals the hypothalamus to reduce appetite. Approximately 15% mean body weight reduction in clinical trials. Common side effects include nausea, especially during dose escalation. Regulatory notice (May 2026): FDA proposed removing Semaglutide from the 503B compounding bulks list — verify current legal status before sourcing compounded versions. Regulatory note (June 2026): The FDA has proposed formally excluding semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list. The public comment period closes June 29, 2026. Compounding availability may change — consult a licensed compounding pharmacy for current status.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Semaglutide (GLP-1): 10mg WEIGHT MANAGEMENT Titrate up from 250mcg to 2.5mg (5 to 50 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Starting dose is 250mcg. GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals the hypothalamus to reduce appetite. Approximately 15% mean body weight reduction in clinical trials. Common side effects include nausea, especially during dose escalation. Regulatory notice (May 2026): FDA proposed removing Semaglutide from the 503B compounding bulks list — verify current legal status before sourcing compounded versions. Regulatory note (June 2026): The FDA has proposed formally excluding semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list. The public comment period closes June 29, 2026. Compounding availability may change — consult a licensed compounding pharmacy for current status.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Semaglutide (GLP-1): 20mg WEIGHT MANAGEMENT Titrate up from 250mcg to 2.5mg (5 to 50 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Starting dose is 250mcg. GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals the hypothalamus to reduce appetite. Approximately 15% mean body weight reduction in clinical trials. Common side effects include nausea, especially during dose escalation. Regulatory notice (May 2026): FDA proposed removing Semaglutide from the 503B compounding bulks list — verify current legal status before sourcing compounded versions. Regulatory note (June 2026): The FDA has proposed formally excluding semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list. The public comment period closes June 29, 2026. Compounding availability may change — consult a licensed compounding pharmacy for current status.
Dosing Calculator
Recommended: 2.0ml BAC water → 10.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Tirzepatide (GLP-1/GIP): 10mg WEIGHT MANAGEMENT Titrate up from 2.5mg to 10mg (25 to 100 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Starting dose is 2.5mg. Dual GIP/GLP-1 receptor agonist. Synergistic receptor co-activation produces approximately 20–21% mean body weight reduction in Phase 3 trials — significantly more than semaglutide mono-agonism. GIP co-activation also reduces GI nausea compared to GLP-1 alone. Titrate slowly. Regulatory notice (May 2026): FDA proposed removing Tirzepatide from the 503B compounding bulks list — verify current legal status before sourcing compounded versions. Regulatory note (June 2026): The FDA has proposed formally excluding semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list. The public comment period closes June 29, 2026. Compounding availability may change — consult a licensed compounding pharmacy for current status.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Tirzepatide (GLP-1/GIP): 30mg WEIGHT MANAGEMENT Titrate up from 2.5mg to 15mg (25 to 150 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Starting dose is 2.5mg. Dual GIP/GLP-1 receptor agonist. Synergistic receptor co-activation produces approximately 20–21% mean body weight reduction in Phase 3 trials — significantly more than semaglutide mono-agonism. GIP co-activation also reduces GI nausea compared to GLP-1 alone. Titrate slowly. Regulatory notice (May 2026): FDA proposed removing Tirzepatide from the 503B compounding bulks list — verify current legal status before sourcing compounded versions. Regulatory note (June 2026): The FDA has proposed formally excluding semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list. The public comment period closes June 29, 2026. Compounding availability may change — consult a licensed compounding pharmacy for current status.
Dosing Calculator
Recommended: 2.0ml BAC water → 15.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Tirzepatide (GLP-1/GIP): 50mg WEIGHT MANAGEMENT Titrate up from 2.5mg to 15mg (15 to 90 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Starting dose is 2.5mg. Dual GIP/GLP-1 receptor agonist. Synergistic receptor co-activation produces approximately 20–21% mean body weight reduction in Phase 3 trials — significantly more than semaglutide mono-agonism. GIP co-activation also reduces GI nausea compared to GLP-1 alone. Titrate slowly. Regulatory notice (May 2026): FDA proposed removing Tirzepatide from the 503B compounding bulks list — verify current legal status before sourcing compounded versions. Regulatory note (June 2026): The FDA has proposed formally excluding semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list. The public comment period closes June 29, 2026. Compounding availability may change — consult a licensed compounding pharmacy for current status.
Dosing Calculator
Recommended: 2.0ml BAC water → 25.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Tirzepatide (GLP-1/GIP): 60mg WEIGHT MANAGEMENT Titrate up from 2.5mg to 15mg (12.5 to 75 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Starting dose is 2.5mg. Dual GIP/GLP-1 receptor agonist. Synergistic receptor co-activation produces approximately 20–21% mean body weight reduction in Phase 3 trials — significantly more than semaglutide mono-agonism. GIP co-activation also reduces GI nausea compared to GLP-1 alone. Titrate slowly. Regulatory notice (May 2026): FDA proposed removing Tirzepatide from the 503B compounding bulks list — verify current legal status before sourcing compounded versions. Regulatory note (June 2026): The FDA has proposed formally excluding semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list. The public comment period closes June 29, 2026. Compounding availability may change — consult a licensed compounding pharmacy for current status.
Dosing Calculator
Recommended: 2.0ml BAC water → 30.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Retatrutide (GLP-1/GIP/Glucagon): 12mg WEIGHT MANAGEMENT Titrate up from 2mg to 12mg (20 to 120 units) Subcutaneous Weekly
Research Notes:
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 TRIUMPH-4 trial (68 weeks, 12mg/week) reported 28.7% mean body weight reduction — the highest published result of any GLP-1-class compound to date. TRIUMPH-2 and TRIUMPH-3 results expected mid–late 2026. NDA filing anticipated Q4 2026; FDA approval realistic 2027 at earliest. 12mg vial suited for maintenance dosing once titration is complete. Not currently FDA approved. Research use only. TRIUMPH-1 Phase 3 data (ADA Scientific Sessions, June 2026): Confirmed 22–24% body weight reduction at the top dose of 12mg at 72 weeks. TRIUMPH-2 and TRIUMPH-3 readouts expected later in 2026. NDA submission anticipated Q4 2026; approval estimated late 2027 to mid-2028. Phase 3 TRIUMPH-4 results (December 2025): The 12mg once-weekly dose achieved 28.7% mean body weight loss over 68 weeks. The 9mg arm produced 26.4% mean loss. A 4mg maintenance dose is under study. This represents the highest published weight loss outcome of any GLP-class compound in Phase 3 trials to date. All use remains research-only. Independent purity testing warning (June 2026): 37 of 37 independently tested grey-market retatrutide samples received failing purity grades per Chainalysis reporting. Source only from vendors providing current, batch-specific HPLC certificates of analysis. Phase 3 outcomes (2026): TRIUMPH-1 (May 2026, n=2,339) demonstrated 28.3% mean weight loss at 12mg weekly — the largest published Phase 3 result of any GLP-1 class compound to date, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints. TRANSCEND-T2D-1 (The Lancet, June 2026): HbA1c reductions up to 2.0% and weight loss up to 16.8% in type 2 diabetes patients at 40 weeks, with no plateau observed. A 4mg maintenance-dose arm is under evaluation. NDA filing expected Q4 2026; FDA approval estimated late 2027–mid-2028. Updated: June 2026.
Dosing Calculator
Recommended: 1.0ml BAC water → 12.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: June 2026 Retatrutide (GLP-1/GIP/Glucagon): 24mg WEIGHT MANAGEMENT Titrate up from 2mg to 12mg (20 to 120 units) Subcutaneous Weekly
Research Notes:
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 TRIUMPH-4 trial (68 weeks, 12mg/week) reported 28.7% mean body weight reduction — the highest published result of any GLP-1-class compound to date. TRIUMPH-2 and TRIUMPH-3 results expected mid–late 2026. NDA filing anticipated Q4 2026; FDA approval realistic 2027 at earliest. 24mg vial suited for maintenance dosing. Not currently FDA approved. Research use only. TRIUMPH-1 Phase 3 data (ADA Scientific Sessions, June 2026): Confirmed 22–24% body weight reduction at the top dose of 12mg at 72 weeks. TRIUMPH-2 and TRIUMPH-3 readouts expected later in 2026. NDA submission anticipated Q4 2026; approval estimated late 2027 to mid-2028. Phase 3 TRIUMPH-4 results (December 2025): The 12mg once-weekly dose achieved 28.7% mean body weight loss over 68 weeks. The 9mg arm produced 26.4% mean loss. A 4mg maintenance dose is under study. This represents the highest published weight loss outcome of any GLP-class compound in Phase 3 trials to date. All use remains research-only. Independent purity testing warning (June 2026): 37 of 37 independently tested grey-market retatrutide samples received failing purity grades per Chainalysis reporting. Source only from vendors providing current, batch-specific HPLC certificates of analysis. Phase 3 outcomes (2026): TRIUMPH-1 (May 2026, n=2,339) demonstrated 28.3% mean weight loss at 12mg weekly — the largest published Phase 3 result of any GLP-1 class compound to date, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints. TRANSCEND-T2D-1 (The Lancet, June 2026): HbA1c reductions up to 2.0% and weight loss up to 16.8% in type 2 diabetes patients at 40 weeks, with no plateau observed. A 4mg maintenance-dose arm is under evaluation. NDA filing expected Q4 2026; FDA approval estimated late 2027–mid-2028. Updated: June 2026.
Dosing Calculator
Recommended: 2.0ml BAC water → 12.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: June 2026 Survodutide: 6mg WEIGHT MANAGEMENT Titrate up from 600mcg to 4.5mg (10 to 75 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Starting dose is 600mcg. Dual agonist of GLP-1 and glucagon receptors. Reduces appetite, drives weight loss, and shows particular efficacy for fatty liver disease (NAFLD/MASH) and chronic fatigue. Phase 3 trials ongoing. Subcutaneous weekly injection. Research compound only.
Dosing Calculator
Recommended: 1.0ml BAC water → 6.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 AOD-9604: 5mg WEIGHT MANAGEMENT 500mcg to 1mg (20 to 40 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted before bed or upon waking (before fasted cardio). Stimulates lipolysis (breakdown of fat) without affecting blood sugar or appetite. Does not carry the growth-promoting effects of full-length HGH. Stacks well with GH peptides and GLP-1 class compounds.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Cagrilintide: 10mg WEIGHT MANAGEMENT 300mcg to 4.5mg (6 to 90 units) Subcutaneous Weekly
Research Notes:
Frequency: once per week. Timing: same day every week. Long-acting amylin analogue. Powerful appetite control via amylin receptor signaling in the hypothalamus and brainstem. When combined with semaglutide as CagriSema, Phase 3 (REDEFINE 4) showed 23% weight loss. NDA filed December 2025; FDA decision expected approximately October 2026. Can reduce required GLP-1 dose. Research compound only. Clinical pipeline note (December 2025): Novo Nordisk filed a New Drug Application (NDA) with the FDA on December 18, 2025 for CagriSema — a fixed-dose weekly combination of cagrilintide + semaglutide for weight management. FDA decision expected approximately October 2026, based on NDA submission date of December 18, 2025 and standard 10–12 month FDA review timeline. In a published head-to-head trial, CagriSema was outperformed by tirzepatide (Zepbound) on weight loss outcomes. Cagrilintide as a standalone compound remains investigational.
Dosing Calculator
Recommended: 1.0ml BAC water → 10.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: June 2026 CJC1295 - No DAC: 10mg GROWTH HORMONE RELEASING HORMONE 1mg to 2mg (10 to 20 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted — before bed or upon waking. Short-acting GHRH analogue. Increases endogenous IGF-1, promotes thermogenesis, and supports lean muscle mass development. Minimal effect on ghrelin, making it well-tolerated. Typically combined with Ipamorelin for a synergistic GH pulse.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 CJC1295 - With DAC: 10mg GROWTH HORMONE RELEASING HORMONE 2mg to 4mg (20 to 40 units) Subcutaneous 1–2x / week
Research Notes:
Frequency: 1 to 2 times per week. Timing: no more than 4mg per week. Long-acting GHRH analogue via Drug Affinity Complex, extending half-life to days. Increases endogenous IGF-1, supports thermogenesis, and promotes lean muscle. Less pulsatile than No-DAC version — suitable for steady baseline GH elevation.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Tesamorelin: 5mg GROWTH HORMONE RELEASING HORMONE 1mg to 2mg (10 to 20 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: taken before bedtime. FDA-approved GHRH analogue (as Egrifta for HIV lipodystrophy). Stimulates the release of endogenous growth hormone, increases IGF-1, and reduces visceral fat. Preferred over HGH for fat loss protocols due to its targeted mechanism.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Tesamorelin: 10mg GROWTH HORMONE RELEASING HORMONE 1mg to 2mg (10 to 20 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: taken before bedtime. FDA-approved GHRH analogue (as Egrifta for HIV lipodystrophy). Stimulates the release of endogenous growth hormone, increases IGF-1, and reduces visceral fat. Preferred over HGH for fat loss protocols due to its targeted mechanism.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Sermorelin: 10mg GROWTH HORMONE RELEASING HORMONE 500mcg to 2mg (10 to 40 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted — 2 hours before the first meal or before bed (or split dosing). Stimulates the release of endogenous growth hormone via GHRH receptor activation. Supports improved muscle strength, growth, and repair. Anti-aging properties via GH/IGF-1 axis. Improves bone density with consistent use.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Sermorelin: 5mg GROWTH HORMONE RELEASING HORMONE 500mcg to 2mg (10 to 40 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted — 2 hours before the first meal or before bed (or split dosing). Stimulates the release of endogenous growth hormone via GHRH receptor activation. Supports improved muscle strength, growth, and repair. Anti-aging properties via GH/IGF-1 axis. Improves bone density with consistent use.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 GHRP-2: 5mg GROWTH HORMONE RELEASING PEPTIDE 150mcg to 300mcg (6 to 12 units) Subcutaneous As needed
Research Notes:
Frequency: as needed. Timing: multiple times daily as needed before meals. Second strongest GHRP. Stimulates the release of endogenous growth hormone and ghrelin. Promotes muscle growth and recovery. Ghrelin increase may raise appetite — factor into nutritional planning.
Dosing Calculator
Recommended: 2.0ml BAC water → 2.5 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 GHRP-6: 5mg GROWTH HORMONE RELEASING PEPTIDE 150mcg to 300mcg (6 to 12 units) Subcutaneous As needed
Research Notes:
Frequency: as needed. Timing: multiple times daily as needed before meals. Third strongest GHRP. Stimulates the release of endogenous growth hormone and ghrelin. Promotes muscle growth and recovery. Significantly increases appetite — commonly used in lean bulking protocols.
Dosing Calculator
Recommended: 2.0ml BAC water → 2.5 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Ipamorelin: 10mg GROWTH HORMONE RELEASING PEPTIDE 200mcg to 300mcg (4 to 6 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: fasted — 30 minutes before each meal, up to 3 times daily. Stimulates the release of endogenous growth hormone without increasing appetite, cortisol, or prolactin — the cleanest GHRP profile available. Promotes lean muscle growth. Best combined with a GHRH peptide (CJC-1295 or Tesamorelin).
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Hexarelin: 5mg GROWTH HORMONE RELEASING PEPTIDE 100mcg (3x day) (4 units) Subcutaneous 3x daily
Research Notes:
Frequency: 3 times daily for 20-week cycles. Most potent GHRP available. Stimulates the release of endogenous growth hormone without increasing appetite. Promotes significant muscle growth. Receptor desensitization occurs with extended use — adhere to 20-week cycle limit.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 HGH 10iu: 10IU HUMAN GROWTH HORMONE 2iu to 6iu (20 to 60 units) Subcutaneous 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off or 3 days on / 1 day off. Timing: fasted — 45 minutes before and after injection. Exogenous human growth hormone. Promotes muscle growth, improves bone density, and regulates metabolism by promoting lipolysis. Requires medical supervision. Not for use without professional guidance.
Dosing Calculator
Reconstitute with 1.0ml BAC water
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 IGF1-LR3: 1mg INSULIN LIKE GROWTH FACTOR 100mcg to 200mcg (10 to 20 units) Intramuscular 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: after a meal or before the gym. Binds IGF-1 receptors to drive muscle growth, fat burning, and increased metabolic rate. Supports muscle recovery and repair. Longer half-life than native IGF-1 due to reduced binding protein affinity.
Dosing Calculator
Recommended: 1.0ml BAC water → 1.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 IGF1-DES: 1mg INSULIN LIKE GROWTH FACTOR 100mcg to 200mcg (10 to 20 units) Intramuscular 5 days on / 2 off
Research Notes:
Frequency: 5 days on / 2 off. Timing: after a meal or before the gym. Truncated IGF-1 variant with approximately 10x greater receptor affinity than IGF-1-LR3 due to reduced binding protein interaction. Best administered IM locally into the target muscle for maximum anabolic effect.
Dosing Calculator
Recommended: 1.0ml BAC water → 1.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Gonadorelin: 5mg GONADOTROPIN RELEASING HORMONE 250mcg (10 units) Subcutaneous Daily
Research Notes:
Frequency: daily or as directed by a physician. Timing: follow dosing protocol based on clinical application. Stimulates gonadotropin release from the pituitary, promoting LH and FSH production and downstream testosterone synthesis. Used for hypogonadism management and TRT support. Physician oversight recommended.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Gonadorelin: 10mg GONADOTROPIN RELEASING HORMONE 250mcg (5 units) Subcutaneous Daily
Research Notes:
Frequency: daily or as directed by a physician. Timing: follow dosing protocol based on clinical application. Stimulates gonadotropin release from the pituitary, promoting LH and FSH production and downstream testosterone synthesis. Used for hypogonadism management and TRT support. Physician oversight recommended.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 HCG: 5000IU REPRODUCTIVE HEALTH 500iu to 1000iu (20 to 40 units) Subcutaneous 2x / week
Research Notes:
Frequency: twice per week. Timing: run 2 to 3 times per year based on individual needs and goals. Treats hypogonadism by directly stimulating the testes to produce testosterone and sperm. In women, used to induce ovulation and support fertilization. Physician oversight strongly recommended.
Dosing Calculator
Reconstitute with 1.0ml BAC water
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Kisspeptin: 5mg REPRODUCTIVE HEALTH 100mcg to 300mcg (4 to 12 units) Subcutaneous As needed
Research Notes:
Frequency: as needed. Potent upstream regulator of the HPG axis. Stimulates GnRH release, which in turn drives LH, FSH, and testosterone production. Useful for hormone balance, reproductive health, and supporting natural testosterone. Often stacked with Gonadorelin in men's hormone protocols.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 BPC-157: 5mg HEALING AND REPAIR 250mcg to 750mcg (10 to 30 units) Subcutaneous or im Daily
Research Notes:
Frequency: daily. Timing: can inject locally near an injury site — works synergistically with TB-500. One of the most studied peptides for healing. Provides neuroprotective, gastroprotective, cardioprotective, and musculoskeletal protective effects via VEGFR2 and ERK1/2 signaling. Over 500 preclinical studies published. Regulatory update (June 2026): PCAC hearing July 23–24, 2026 may restore BPC-157 to the 503A compounding bulks list. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 BPC-157: 10mg HEALING AND REPAIR 250mcg to 750mcg (5 to 15 units) Subcutaneous or im Daily
Research Notes:
Frequency: daily. Timing: can inject locally near an injury site — works synergistically with TB-500. One of the most studied peptides for healing. Provides neuroprotective, gastroprotective, cardioprotective, and musculoskeletal protective effects via VEGFR2 and ERK1/2 signaling. Over 500 preclinical studies published. Regulatory update (June 2026): PCAC hearing July 23–24, 2026 may restore BPC-157 to the 503A compounding bulks list. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 TB-500: 5mg HEALING AND REPAIR 2.5 to 5mg (50 to 100 units) Subcutaneous 2x / week
Research Notes:
Frequency: twice per week. Timing: works synergistically with BPC-157. Decreases inflammation and binds to actin via the thymosin beta-4 fragment to accelerate cell migration into injury sites. Accelerates wound healing of joints and muscles. Acts systemically — does not need to be injected at the injury site. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 TB-500: 10mg HEALING AND REPAIR 2.5 to 5mg (25 to 50 units) Subcutaneous 2x / week
Research Notes:
Frequency: twice per week. Timing: works synergistically with BPC-157. Decreases inflammation and binds to actin via the thymosin beta-4 fragment to accelerate cell migration into injury sites. Accelerates wound healing of joints and muscles. Acts systemically — does not need to be injected at the injury site. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 Wolverine Blend: BPC-157 (10mg) / TB500 (10mg) HEALING AND REPAIR 500mcg to 1mg (10 to 20 units) Subcutaneous or im 5–7 days / week
Research Notes:
Frequency: 5 to 7 days per week. Timing: BPC-157 can be injected near the injury site; TB-500 acts systemically and does not need to be localized. Complementary healing mechanisms: BPC-157 drives vascularization and local repair; TB-500 promotes broad cell migration and tissue organization. Enhances skin health, accelerates healing, and supports overall tissue regeneration. Regulatory update (June 2026): PCAC hearing July 23–24, 2026 may restore BPC-157 to the 503A compounding bulks list.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: June 2026 BPC-157 Oral Tablets GUT HEALING 500mcg to 1000mcg (1 to 2 tablets) Oral tablets Daily
Research Notes:
Frequency: daily. Timing: take with meals. BPC-157 in oral form for gastrointestinal applications. Chemically stable in gastric juice (originally isolated from gastric juice), allowing it to retain biological activity through the GI tract. Studied for gut lining repair, inflammatory bowel disease, NSAID-induced gastric injury, and leaky gut. Regulatory update (June 2026): PCAC hearing July 23–24, 2026 may restore BPC-157 to the 503A compounding bulks list.
Dosing Calculator
Oral — no reconstitution needed
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: June 2026 Epithalon: 10mg LONGEVITY 10mg (100 units) Subcutaneous Cycle (20 days)
Research Notes:
Frequency: daily for 20 days (one full vial per day), 2 to 3 cycles per year. One of very few compounds with documented telomerase activation in vitro and animal studies. Works on the pineal gland of the brain. Anti-aging effects include lengthening telomere caps on DNA and restoring melatonin to youthful levels via pineal normalization. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 1.0ml BAC water → 10.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 Epithalon: 50mg LONGEVITY 10mg to 20mg (40 to 80 units) Subcutaneous Cycle (10–20 days)
Research Notes:
Frequency: 4-vial cycle over 10 to 20 days, 3 cycles per year. One of very few compounds with documented telomerase activation in vitro and animal studies. Works on the pineal gland of the brain. Anti-aging effects include lengthening telomere caps on DNA and restoring melatonin to youthful levels via pineal normalization. Larger vial for multi-cycle convenience. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 2.0ml BAC water → 25.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 PE-22-28: 10mg BRAIN + MOOD 300mcg to 1mg (3 to 10 units) Subcutaneous Daily
Research Notes:
Frequency: daily. Innovative neuroprotective peptide. Studied for cognitive support, mood stabilization, and neuroplasticity enhancement. Often included in the Calm + Clarity blend alongside Selank and Pinealon.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 NAD+: 1000mg LONGEVITY / MITOCHONDRIAL FUNCTION 50mg to 150mg (10 to 30 units) Intramuscular Weekly
Research Notes:
Frequency: 10 units daily or 20 to 30 units twice per week. Timing: single dose not to exceed 250mg (50 units). Required coenzyme for DNA repair, cellular energy production (ATP via the electron transport chain), and sirtuin activation (SIRT1–SIRT7). NAD+ levels decline approximately 50% between ages 40 and 60. Injectable NAD+ bypasses the conversion steps required by oral NMN or NR precursors for more direct bioavailability.
Dosing Calculator
Recommended: 2.0ml BAC water → 500.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Oxytocin: 10mg BRAIN + MOOD 250mcg to 500mcg (5 to 10 units) Subcutaneous Daily
Research Notes:
Frequency: daily. Known as the "love hormone." Increases social bonding, emotional well-being, and feelings of trust. Helps reduce stress and anxiety. Studied for supportive use in social anxiety, relationship health, and overall mood.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Semax: 30mg BRAIN + MOOD 500mcg to 1000mcg (5 to 10 units) Subcutaneous Daily
Research Notes:
Frequency: daily. Synthetic heptapeptide derived from ACTH. Triggers release of brain-derived neurotrophic factor (BDNF). Enhances neuroplasticity and helps the brain learn and adapt faster. Improves cerebral blood flow. Approved pharmaceutical in Russia for stroke recovery and cognitive disorders since the 1990s. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 2.0ml BAC water → 15.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 Selank: 5mg BRAIN + MOOD 250mcg to 500mcg (5 to 10 units) Subcutaneous Daily
Research Notes:
Frequency: daily. Anti-anxiety peptide that modulates GABAergic signaling and increases serotonin and dopamine activity. Enhances learning capacity and memory consolidation. Documented anxiolytic effects in human studies. Often combined with Semax for complementary cognitive and mood benefits.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Selank: 10mg BRAIN + MOOD 250mcg to 500mcg (5 to 10 units) Subcutaneous Daily
Research Notes:
Frequency: daily. Anti-anxiety peptide that modulates GABAergic signaling and increases serotonin and dopamine activity. Enhances learning capacity and memory consolidation. Documented anxiolytic effects in human studies. Often combined with Semax for complementary cognitive and mood benefits. Higher vial concentration — recommended for extended research protocols. Same dosing range (250mcg–500mcg per injection); the 10mg vial provides greater value for longer cycles. Updated: June 2026
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Follistatin 344: 1mg MUSCLE DEVELOPMENT 200mcg (20 units) Intramuscular Cycle (20 days)
Research Notes:
Frequency: 4-vial cycle over 20 days, 3 cycles per year. Myostatin inhibitor. Promotes increased muscle mass and strength by blocking the inhibitory protein that limits muscle growth. Treats muscular atrophy and reduces cortisol. Administer IM into the target muscle group.
Dosing Calculator
Recommended: 1.0ml BAC water → 1.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 MOTS-c: 10mg MITOCHONDRIAL FUNCTION 5mg - 10mg (50 units - 100 units) Subcutaneous Cycle (every 5 days)
Research Notes:
Frequency: 1 injection every 5 days for 20 days, 2 to 3 cycles per year. Timing: if Type 2 diabetic, 1mg every other day. Often called "exercise in a bottle." Activates AMPK signaling to convert available glucose into mitochondrial energy. Strong anti-aging effects and documented benefits for Type 2 diabetes and insulin resistance. Mitochondrial DNA-encoded peptide that declines significantly with age. Expanding research scope (2025–2026): New studies in neuroprotection and pancreatic islet cell senescence (Nature, 2025). MOTS-c is now one of the most researched mitochondrially-derived peptides alongside Humanin and the SHLP series. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 SS-31: 14mg MITOCHONDRIAL FUNCTION 4.67mg (40 units) Subcutaneous Cycle (21 days)
Research Notes:
Frequency: 7-vial cycle at one vial per day for 21 days, 2 to 3 cycles per year. Timing: best run before a MOTS-c cycle to prepare the mitochondrial membrane. Targets the inner membrane of mitochondria. Enhanced protection and restoration of mitochondrial function results in increased ATP production. Supports brain function and has demonstrated anti-cancer properties in preclinical research. Phase III human clinical trial data from the Barth Syndrome study (40mg daily, 48 weeks) showed trends toward cardiac improvement — the most advanced human clinical evidence in the mitochondrial peptide class to date.
Dosing Calculator
Recommended: 2.0ml BAC water → 7.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Tesofensine Oral Tablets: 15mg BRAIN + WEIGHTLOSS 250mcg to 1000mcg (1/2 to 2 tablets) Oral tablets Daily
Research Notes:
Frequency: daily. Timing: fasted upon waking. Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). Enhances mood, suppresses appetite, increases energy, and supports cognitive function. Oral administration — no injection required.
Dosing Calculator
Oral — no reconstitution needed
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Tesofensine Oral Tablets: 50mg BRAIN + WEIGHTLOSS 250mcg to 1000mcg (1/2 to 2 tablets) Oral tablets Daily
Research Notes:
Frequency: daily. Timing: fasted upon waking. Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). Enhances mood, suppresses appetite, increases energy, and supports cognitive function. Oral administration — no injection required.
Dosing Calculator
Oral — no reconstitution needed
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 DSIP: 5mg DELTA SLEEP/DETOX/WITHDRAWAL 500mcg to 1mg (10 to 20 units) Subcutaneous As needed
Research Notes:
Frequency: as needed before bed. Delta sleep-inducing peptide. Resets the circadian clock and supports normal sleep architecture. Also provides support for the nervous and hormonal systems. Studied for use in alcohol and opioid withdrawal management. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 PT-141: 5mg LIBIDO/ED 500mcg (10 units) Subcutaneous As needed
Research Notes:
Frequency: as needed (approximately 2 hours before sexual activity). Timing: do not exceed 20 units per dose; consult a physician. Signals the central nervous system to enhance blood flow, arousal, and libido in both men and women. Acts via melanocortin receptors — distinct from PDE5 inhibitors like sildenafil.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 PT-141: 10mg LIBIDO/ED 500mcg to 1mg (10 to 20 units) Subcutaneous As needed
Research Notes:
Frequency: as needed (approximately 2 hours before sexual activity). Timing: do not exceed 20 units per dose; consult a physician. Signals the central nervous system to enhance blood flow, arousal, and libido in both men and women. Acts via melanocortin receptors — distinct from PDE5 inhibitors like sildenafil.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Melanotan I (MT-I): 10mg MELANIN/LIBIDO 500mcg to 1mg (5 to 10 units) Subcutaneous Every other day
Research Notes:
Frequency: every other day. Timing: administer approximately 30 minutes before tanning. Used for melanogenesis (skin tanning) via alpha-MSH receptor activation. Also studied for appetite suppression and enhanced sexual stimulus at higher doses.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Melanotan II (MT-II): 10mg MELANIN/LIBIDO 500mcg to 1mg (5 to 10 units) Subcutaneous As needed
Research Notes:
Frequency: as needed before tanning. Timing: administer approximately 30 minutes before tanning. Used for melanogenesis (skin tanning), appetite suppression, and enhanced sexual stimulus. More potent than MT-I with a shorter dosing schedule. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 BDNF: 10mg BRAIN + REPAIR 500mcg to 2mg (5 to 20 units) Subcutaneous Daily
Research Notes:
Frequency: daily. Brain-derived neurotrophic factor. Stimulates neurogenesis, enhances cognition, and supports mood regulation, memory, and learning. Key peptide for long-term brain health and neuroplasticity.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 LL-37 Complex: 5mg IMMUNITY 250mcg (10 units) Subcutaneous As needed
Research Notes:
Frequency: while sick or to prevent illness. Timing: stop use when feeling healthy. Antimicrobial, antiviral, and antibiofilm properties. Used as a natural antibiotic that fights lung and gut infections. The complex formulation provides broader antimicrobial coverage.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 LL-37: 5mg IMMUNITY 300mcg to 1mg (12 to 50 units) Subcutaneous As needed
Research Notes:
Frequency: during illness. Timing: stop use when feeling healthy. Antimicrobial, antiviral, and antibiofilm properties. Used as a natural antibiotic targeting lung and gut infections. Only known human cathelicidin antimicrobial peptide. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 GHK-Cu: 50mg HAIR/SKIN/COLLAGEN 1mg to 2mg (4 to 8 units) Subcutaneous Daily
Research Notes:
Frequency: daily. Timing: 30 days on / 14 days off. Copper tripeptide that tightens loose skin, reduces fine lines and wrinkles, fights hair loss, promotes wound healing, supports bone repair, and reduces inflammation. Activates approximately 31% of human tissue remodeling genes. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 2.0ml BAC water → 25.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 GHK-Cu: 75mg HAIR/SKIN/COLLAGEN 1mg to 2mg (3 to 5 units) Subcutaneous Daily
Research Notes:
Frequency: daily. Timing: 30 days on / 14 days off. Copper tripeptide that tightens loose skin, reduces fine lines and wrinkles, fights hair loss, promotes wound healing, supports bone repair, and reduces inflammation. Larger vial for extended cycles. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 3.0ml BAC water → 25.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 KPV: 5mg ANTI-VIRAL, ANTI-MICROBIAL 200mcg to 500mcg (5 to 10 units) Subcutaneous As needed
Research Notes:
Frequency: based on injury or illness. Timing: applicable after surgery, preventatively, or during illness. Reduces inflammatory cytokines, promotes wound healing, and provides antimicrobial support. Particularly studied for inflammatory bowel disease and mucosal barrier repair. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 Curcumin: 600mg ANTI INFLAMMATORY 45-90 mg (15 to 30 units) Intramuscular Daily
Research Notes:
Frequency: daily. Injectable curcumin compound. Modulates inflammatory pathways via NF-kB inhibition. Promotes tissue repair, provides antioxidant activity, and supports gut health. 45–90mg IM daily is the typical research protocol.
Dosing Calculator
Recommended: 2.0ml BAC water → 300.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 PEPITEM: 5mg ANTI INFLAMMATORY [needs review — no published human dosing data found; preclinical models used 100nm–10μm in vitro; in vivo murine mg/kg dose not specified in published abstracts per doi:10.1016/j.phrs.2025.107624] Subcutaneous [NEEDS REVIEW]
Research Notes:
Frequency: [NEEDS REVIEW — no established human protocol]. Timing: subcutaneous injection based on preclinical administration models; topical application studied in psoriasis models. PEPITEM is a 14-amino-acid endogenous peptide (SVTEQGAELSNEER) released by B lymphocytes in response to adiponectin signalling. Its mechanism targets the vascular checkpoint that controls whether T lymphocytes cross vessel walls into tissue: adiponectin binds receptors on B cells, triggering PEPITEM secretion; PEPITEM binds Cadherin-15 on activated endothelial cells; local sphingosine-1-phosphate (S1P) is produced; S1P signals crawling T cells to detach, blocking their migration without disrupting neutrophil or monocyte recruitment. Innate immune function is preserved — a key distinction from corticosteroids and most anti-cytokine biologics (Chimen et al. Nature Medicine 2015; PMID 25894827). A 2024 npj Aging paper (doi:10.1038/s41514-024-00160-6) demonstrated that adiponectin receptor expression on B cells declines with age, reducing endogenous PEPITEM levels and allowing progressive T-cell infiltration of metabolically active tissues — a direct molecular mechanism for inflammaging. Exogenous PEPITEM normalised leukocyte trafficking in aged mice to approximate young-animal phenotype. In 2026, an Arthritis and Rheumatology paper proposed 'PEPITEM replacement therapy' — restoring a physiological brake that age erodes, rather than suppressing immunity broadly (doi:10.1002/art.70108). A secondary bone pathway via NCAM-1 signalling on osteoblasts has also been characterised, with dual anabolic and anti-resorptive effects in osteoporosis models (Lewis et al. 2024; Frost et al. Biomedicine and Pharmacotherapy 2025, PMID 40876366). Disease models studied include rheumatoid arthritis, psoriatic arthritis, lupus, multiple sclerosis (EAE), psoriasis, gouty arthritis, and metabolic inflammation. As of July 2026, no human clinical trials have been registered or completed. Research compound only. Not FDA-approved. Consult a qualified healthcare professional.
Dosing Calculator
[NEEDS REVIEW — reconstitution protocol not established in published human research]
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: July 2026 TA-1 Complex: 16.4mg ANTI-VIRAL + ANTI CANCER + IMMUNITY 3mg to 8mg (20 - 50 units) Intramuscular 2x / week
Research Notes:
Frequency: twice per week when sick, up to 4 times per year. Timing: use when sick. Thymosin alpha-1 stimulates the immune system by producing and activating T-cells, dendritic cells, and natural killer cells. Eradicates bacteria, fungi, and viruses. The complex formulation provides enhanced immune activation.
Dosing Calculator
Recommended: 1.0ml BAC water → 16.4 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 TA-1: 10mg ANTI-VIRAL + ANTI CANCER + IMMUNITY 3mg to 8mg (30 - 80 units) Intramuscular 2x / week
Research Notes:
Frequency: twice per week when sick, up to 4 times per year. Timing: use when sick. Thymosin alpha-1 stimulates the immune system by producing and activating T-cells, dendritic cells, and natural killer cells. Anti-viral, anti-fungal, and immune-modulating properties.
Dosing Calculator
Recommended: 1.0ml BAC water → 10.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Glow: GHK-Cu (27mg) / BPC-157 (5mg) / TB500 (10mg) SKIN + TISSUE HEALING 900mcg to 1800mcg (10 - 20 units) Subcutaneous Daily
Research Notes:
Frequency: daily. Multi-compound blend for skin health and tissue regeneration. GHK-Cu promotes collagen synthesis and skin tightening. BPC-157 drives angiogenesis and local healing. TB-500 promotes cell migration for broader tissue organization. Visible improvements typically occur at 4–6 weeks.
Dosing Calculator
Recommended: 2.0ml BAC water → 13.5 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Retatrutide (GLP-1/GIP/Glucagon): 6mg WEIGHT MANAGEMENT 1mg to 9mg (10 to 90 units) Subcutaneous Weekly
Research Notes:
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 TRIUMPH-4 trial (68 weeks, 12mg/week) reported 28.7% mean body weight reduction — the highest published result of any GLP-1-class compound to date. TRIUMPH-2 and TRIUMPH-3 results expected mid–late 2026. NDA filing anticipated Q4 2026; FDA approval realistic 2027 at earliest. Not currently FDA approved. Research use only. Titrate: 1mg for 4 weeks, increase by 2mg every 4 weeks to maintenance. TRIUMPH-1 Phase 3 data (ADA Scientific Sessions, June 2026): Confirmed 22–24% body weight reduction at the top dose of 12mg at 72 weeks. TRIUMPH-2 and TRIUMPH-3 readouts expected later in 2026. NDA submission anticipated Q4 2026; approval estimated late 2027 to mid-2028. Independent purity testing warning (June 2026): 37 of 37 independently tested grey-market retatrutide samples received failing purity grades per Chainalysis reporting. Source only from vendors providing current, batch-specific HPLC certificates of analysis.
Dosing Calculator
Recommended: 1.0ml BAC water → 6.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: June 2026 CagriSema Blend (Cagrilintide + Semaglutide): 10mg WEIGHT MANAGEMENT Titrate from 0.25mg each to 2.4mg each (2.5 to 24 units) Subcutaneous Weekly
Research Notes:
Fixed-dose combination of Cagrilintide (amylin analogue) and Semaglutide (GLP-1 agonist). REDEFINE 4 trial showed 23% weight loss — strong efficacy just below tirzepatide non-inferiority threshold. Novo Nordisk NDA filed December 2025. FDA review decision expected approximately October 2026. Not FDA approved. Research use only. Regulatory note (June 2026): The FDA has proposed formally excluding semaglutide and tirzepatide from the 503B outsourcing facility bulk drug substances list. The public comment period closes June 29, 2026. Compounding availability may change — consult a licensed compounding pharmacy for current status. NDA filed with the FDA on December 18, 2025 by Novo Nordisk. Currently under FDA review. REDEFINE 1 trial results: 91.9% of participants achieved ≥5% body weight reduction vs 31.5% in the placebo group. First once-weekly GLP-1 + amylin analogue combination under FDA review. Approval decision expected in 2026. Note: CagriSema (cagrilintide + semaglutide) received full FDA approval as a branded weight-management drug on May 25, 2026. This dosing entry refers to the compounded research-peptide version, which is a separate legal and supply category from the FDA-approved branded product.
Dosing Calculator
Recommended: 1.0ml BAC water → 10.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Humanin: 5mg LONGEVITY / MITOCHONDRIAL FUNCTION 2mg to 4mg (40 to 80 units) Subcutaneous or intramuscular 3x / week
Research Notes:
Mitochondria-derived peptide (MDP) that declines naturally with age. Exerts cytoprotective effects by blocking pro-apoptotic Bax protein, reduces oxidative stress, and supports cellular energy production. Often stacked with MOTS-c and SS-31 in longevity protocols as the three key MDPs. Research compound only.
Dosing Calculator
Recommended: 1.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Dihexa: 10mg BRAIN + COGNITIVE 1mg to 2mg (10 to 20 units) Subcutaneous Daily
Research Notes:
Synthetic peptide derived from angiotensin IV sequences. Studied for synaptogenesis via high-affinity HGF/Met signaling. Designed to penetrate the blood-brain barrier. Important caveat: the foundational 2014 mechanism paper was formally retracted in April 2025 due to falsified data — no approved human clinical trials exist. Research compound only. Recommended: 4–6 week cycles with breaks; do not run indefinitely. Regulatory update (April 2026): This peptide was removed from the FDA's Category 2 'Do Not Compound' list effective April 22, 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review it for addition to the 503A bulk substances list at meetings scheduled July 23–24, 2026.
Dosing Calculator
Recommended: 1.0ml BAC water → 10.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 5-Amino-1MQ: 50mg oral capsules LONGEVITY / MITOCHONDRIAL FUNCTION 50mg to 100mg (1 to 2 capsules) Oral Daily
Research Notes:
NNMT (nicotinamide N-methyltransferase) inhibitor. Research suggests support for fat cell metabolism, increased NAD+ availability, and mitochondrial function. Oral administration — no reconstitution required. Research compound only.
Dosing Calculator
Oral — no reconstitution needed
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 VIP (Vasoactive Intestinal Peptide): 5mg IMMUNITY 50mcg to 100mcg (5 to 10 units) Subcutaneous or intranasal 2x daily
Research Notes:
Endogenous neuropeptide with potent immune-modulating and anti-inflammatory properties. Binds VPAC1 and VPAC2 receptors to reduce IL-6 and TNF-alpha production. Studied for chronic inflammatory conditions, mast cell activation syndrome (MCAS), autoimmune support, and circadian rhythm dysregulation. Research compound only.
Dosing Calculator
Recommended: 2.0ml BAC water → 2.5 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Pinealon: 20mg BRAIN + COGNITIVE 1mg to 3mg (10 to 30 units) Subcutaneous Daily (10-day cycles)
Research Notes:
Neuroprotective tripeptide (Glu-Asp-Arg). Studied for circadian rhythm support, pineal gland function, and neuroprotection. Epigenetic regulation of memory and neurogenesis genes. Run as 10-day cycles 2–4 times per year, similar to Epithalon. Often combined with Epithalon in longevity protocols and with Selank + PE-22-28 in the Calm + Clarity stack. Research compound only.
Dosing Calculator
Recommended: 2.0ml BAC water → 10.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Wolverine+: BPC-157 (10mg) / TB-500 (10mg) / NAD+ (500mg) HEALING AND REPAIR Per component (see individual entries) Subcutaneous / intramuscular Mixed (see notes)
Research Notes:
Enhanced Wolverine stack. BPC-157 supports local tissue repair (daily SubQ). TB-500 acts systemically for cell migration and tissue organization (twice weekly SubQ). NAD+ provides mitochondrial energy to fuel the repair process (weekly IM). Reconstitute each component separately. Administer as separate injections per component protocol. Regulatory update (May 2026): PCAC hearing July 23–24, 2026 may restore BPC-157 to the 503A compounding bulks list.
Dosing Calculator
Oral — no reconstitution needed
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 KLOW: GHK-Cu (27mg) / KPV (5mg) / BPC-157 (5mg) / TB-500 (10mg) SKIN + TISSUE HEALING 900mcg to 1800mcg (10 to 20 units) Subcutaneous Daily
Research Notes:
Multi-compound blend for skin rejuvenation and tissue repair. GHK-Cu promotes collagen and elastin synthesis. KPV provides anti-inflammatory and antimicrobial support via melanocortin receptors. BPC-157 supports blood flow and local repair via VEGFR2. TB-500 promotes cell migration for broader tissue organization. Visible improvements typically at 4–6 weeks. Regulatory update (May 2026): PCAC hearing July 23–24, 2026 may restore BPC-157 to the 503A compounding bulks list.
Dosing Calculator
Recommended: 2.0ml BAC water → 13.5 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: May 2026 Oral Semaglutide (Wegovy® Pill): 7mg WEIGHT MANAGEMENT 7mg to 14mg (1 to 2 tablets) Oral tablets Daily
Research Notes:
Frequency: once daily. Timing: 30 minutes before first food or drink of the day, with no more than 4 oz plain water. FDA-approved oral semaglutide (Wegovy® Pill) was launched in January 2026 — the first oral GLP-1 receptor agonist approved for weight management in the United States. Clinical trial data (OASIS 2): 15.1% mean body weight reduction at 68 weeks vs 2.4% placebo. The oral form uses a SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer to allow GLP-1 passage through the gastric mucosa, achieving approximately 1% bioavailability compared to subcutaneous injection. Dose escalation: 7mg once daily for 4 weeks, then 14mg once daily. Must be taken on an empty stomach at least 30 minutes before first food, beverage, or other oral medications, with no more than 4 oz (120 ml) of plain water — other liquids reduce absorption. Over 3 million US prescriptions issued as of mid-2026. This is an FDA-approved pharmaceutical — not a research peptide.
Dosing Calculator
Oral — no reconstitution needed
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: June 2026 SLU-PP-332: 10mg FAT LOSS / LEAN MUSCLE 1mg to 5mg (10 to 50 units) Subcutaneous 3x Weekly
Research Notes:
Frequency: 3 times per week. Timing: fasted or pre-workout. SLU-PP-332 is a synthetic ERR (estrogen-related receptor) pan-agonist developed at Saint Louis University. ERRα, ERRβ, and ERRγ are nuclear receptors that regulate mitochondrial biogenesis and oxidative metabolism. In preclinical rodent studies, SLU-PP-332 increased treadmill running capacity by approximately 70%, reduced body fat, and stimulated mitochondrial gene expression programs similar to endurance exercise — earning it the informal name ‘exercise in a bottle’ in preclinical research coverage. Published in Nature Communications (2023). As of June 2026, there are no human clinical trials, no FDA approval, and no approved therapeutic use. Early-stage research only. Not available from licensed compounding pharmacies. Grey-market sources carry unknown purity risks.
Dosing Calculator
Recommended: 2.0ml BAC water → 5.0 mg/ml
Concentration (mg/ml)
Desired Dose (mcg)
Volume (ml)
Syringe Units
Updated: June 2026 MK-677 (Ibutamoren) GROWTH HORMONE RELEASING PEPTIDE 10mg to 25mg Oral Daily (before bed)
Research Notes:
Frequency: daily (before bed). MK-677 is a non-peptide GH secretagogue (ghrelin receptor agonist), often grouped with peptide GH secretagogues like Ipamorelin and CJC-1295 but chemically distinct. It is not a peptide and is not subject to the FDA’s peptide Category 2/503A compounding review process — different regulatory track entirely.
Updated: June 2026